title: Effect of recombinant human interleukin-11 on motilin and substance P release in normal and inflamed rabbits.
abstract: Recombinant human interleukin-11 (rhIL-11) normalizes depressed smooth muscle tension generation towards motilin and substance P (SP) in rabbits with colitis. The aim of this paper was to evaluate the effect of rhIL-11 treatment on motilin and SP release which could have an effect on the contractility changes. Rabbits received 4, 40, 72 or 720 microg/kg rhIL-11 s.c. or saline, 1 h later a continuous s.c. administration of rhIL-11 was started with or without the induction of colitis (135 mg/kg TNBS) for 5 days. Motilin and SP levels were measured by RIA, motilin mRNA expression by RT-PCR. TNBS-colitis did not affect plasma motilin levels but increased the motilin content of the duodenal mucosa 1.7-fold. rhIL-11 treatment dose-dependently increased plasma motilin levels (720 microg/kg day: 3.5-fold) and the motilin content of the duodenal mucosa (720 microg/kg day: 3.0-fold). The effects of rhIL-11 were similar in normal rabbits and were accompanied by an increased motilin mRNA expression. TNBS-colitis decreased plasma SP levels 2.7-fold and the SP content in the colonic muscle layer 7.1-fold. The decrease in the muscle layer, but not in the plasma, was normalized by rhIL-11 treatment. In normal rabbits, rhIL-11 caused a decrease in plasma SP levels, but had no effect on the tissue content of SP. In conclusion, treatment of inflamed or normal rabbits with rhIL-11 increases plasma and tissue levels of motilin in the duodenal mucosa via an increased expression of motilin in the endocrine cells and induces the release of SP from extrinsic neurons. These changes do not explain the beneficial effect of rhIL-11 on the lowered contractility in inflamed rabbits although a change in balance of neuropeptides may influence gastro-intestinal inflammation.
authors.affiliation: Centre for Gastroenterological Research, Department of Pathophysiology, University of Leuven, Gasthuisberg O&N, B-3000 Leuven, Belgium.
authors.forename: I
authors.initials: I
authors.lastname: Depoortere
authors.forename: T
authors.initials: T
authors.lastname: Thijs
authors.forename: L
authors.initials: L
authors.lastname: Thielemans
authors.forename: J C
authors.initials: JC
authors.lastname: Keith
authors.forename: G
authors.initials: G
authors.lastname: Van Assche
authors.forename: T L
authors.initials: TL
authors.lastname: Peeters
mesh_terms: D000818:Animals; D001483:Base Sequence; D003092:Colitis / Q000378:metabolism*; D017931:DNA Primers; D005260:Female; D006801:Humans; D017370:Interleukin-11 / Q000097:blood / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000378:metabolism; D008297:Male; D009037:Motilin / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011817:Rabbits; D011994:Recombinant Proteins / Q000097:blood / Q000494:pharmacology; D013373:Substance P / Q000378:metabolism*
chemical_list: D017931:DNA Primers; D017370:Interleukin-11; D012333:RNA, Messenger; D011994:Recombinant Proteins; D013373:Substance P; D009037:Motilin